Theravance Biopharma, Inc.
TBPH · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $738 | $553 | $444 | $464 |
| - Cash | $175 | $282 | $111 | $38 |
| + Debt | $45 | $46 | $48 | $50 |
| Enterprise Value | $607 | $318 | $381 | $476 |
| Revenue | $20 | $26 | $15 | $19 |
| % Growth | -23.7% | 70.2% | -17.9% | – |
| Gross Profit | $12 | $16 | $4 | $19 |
| % Margin | 59.4% | 60% | 25.6% | 100% |
| EBITDA | -$2 | -$2 | -$14 | -$8 |
| % Margin | -9.5% | -8.8% | -91.1% | -40.5% |
| Net Income | $4 | $55 | -$14 | -$16 |
| % Margin | 18.1% | 209.3% | -88.2% | -82.8% |
| EPS Diluted | 0.07 | 1.08 | -0.27 | -0.31 |
| % Growth | -93.5% | 500% | 12.9% | – |
| Operating Cash Flow | -$7 | $208 | $43 | -$1 |
| Capital Expenditures | $0 | -$0 | $0 | -$0 |
| Free Cash Flow | -$7 | $208 | $43 | -$1 |